Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{153852,
        author = {Dr. Keerthi G S Nair and Dr. P Manoj Kumar},
        title = {Target delivery of remdesivir may minimize the hepatotoxicity in COVID-19},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {8},
        number = {9},
        pages = {97-99},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=153852},
        abstract = {Remdesivir is a broad-spectrum antiviral agent meant to inhibit viral RNA polymerases against members of several virus families, including filoviruses. Although reported for significant clinical improvements in COVID-19, a detailed observation of the connection with the drawbacks of remdesivir therapy was poor pulmonary distribution and hepatotoxicity (transaminase elevation) was recorded that resulted in discontinuation of remdesivir therapy. Nanodrug delivery facilitates a large drug payload to the targeted site improving the efficacy. With the lesser dose administered, could be expected for minimized adverse events. Additional payload of ashwagandha will protect the liver from the damages caused if any. Remdesivir may be a safe and an effective therapeutic agent for COVID 19 when co-administered with ashwagandha as nanoparticles},
        keywords = {COVID-19; Hepatotoxicity; Remdesivir; Nanoparticle; Target delivery; Improved clinical outcome},
        month = {},
        }